Sterling Vascular Inc.

1
Sterling Vascular Inc.

• Presentation

2
Sterling Vascular Profile

• Developer of next generation of Coronary Drug
  Eluting Stent (DES) to address safety issues of
  late stent thrombosis
• Incorporated in 2008 in Delaware
• Registered as Sterling Medical Devices Suzhou LLT
  in Biobay Science park in China.
• Initial Market entry Asia, South America/ EU
  then USA
• Filed Provisional patent in the USA, to be
  applied WW
• Seeking Equity Funding to conduct in vivo trials
• Have identified potential distribution partners
  in China

3
Management Team

• Robert Ndondo-Lay- Founder/President
• Biosensors for 3 years as GM (Europe)
• Former RD engineer at Guidant, Medtronic, Boston
  Scientific
• BS/MBA
• Scott Olson Co-Founder / CEO
• Biosensors for 8 years as EVP and COO
• Sorin and Shiley 25 years in various positions
• BS in Business Administration , University of La
  Verne in California, USA and graduated Cum Laude.
  
• Xin Ying- General Manager
• Weigao Medical products for 12 years (China)
• 3 Years Medical Product Automation (China)
• Advisory Group
• Sepehr Fariabi, PhD, ( Material)
• Julien Lee, PhD, ( Medical Sciences)
• Patty Kiang, PhD,MBA ( Pharma kinetics)
• Yong Zhu, PhD,MBA ( Finance and Advisor
  in China)

4
Coronary Artery DiseaseThe Most Common Type of
Heart Disease
Narrowing of coronary arteries carrying blood to
heart
Caused by accumulation of fat-laden cells/plaque

• A leading cause of death worldwide 7.1 million
  in 2001 growing to 11.1 million in 2020

5
Coronary Artery DiseasePresent day treatment -
DES
Narrowing of coronary arteries carrying blood to
heart
Caused by accumulation of fat-laden cells/plaque

• A leading cause of death worldwide 7.1 million
  in 2001 growing to 11.1 million in 2020

6
Safety Concerns Over DES

• Some Doctors See Long-Term Clot Risk in Stent
  Patients, Wall Street Journal, 21 October 2005
• Concerns Prompt Some Hospitals to Pare Use of
  Drug-Coated Stents, Wall Street Journal, 22 June
  2006

7
Dilemma in using Plavix (Clopidogrel)

• Patients implanted with drug eluting stents are
  prescribed Plavix for longer duration
• Real Problems with taking long term Plavix
• High risk of bleeding/Additional needed surgeries
  on any type
• Some patients are not compliant with medication
  regimen, creating high risk of premature death
  (thrombosis)
• Plavix is expensive
• Plavix is not effective in some patients

Dangers of Stopping Clopidogrel (Plavix) for
Patients with Stents and Certain Other
Conditions A Public Health Alert from the
American College of Cardiology BETHESDA, Md.,
March 16, 2006 /PRNewswire/ -- Recent media
reports regarding the results of the CHARISMA
Trial may be misinterpreted by patients with
coronary stents and other conditions, causing
these patients to inappropriately stop taking the
anti-clotting drug clopidogrel (Plavix(R)).
Patients taking Plavix(R) for any reason should
consult with their cardiologist or other health
care provider before stopping this medication.
The CHARISMA Trial was presented at the Annual
Scientific Sessions of the of Cardiology on
Sunday, March 12 in Atlanta and simultaneously
published in the New England Journal of Medicine.
Although the CHARISMA trial showed no benefit to
combining Plavix(R) and aspirin and for certain
patients, this study does not invalidate use of
the drug for approved indications, such as
stenting. Certain other patients are given
Plavix(R) after hospitalization for heart attack
or stroke. Patients with these conditions must
discuss the benefits and risks of anti-clotting
medication with their health care provider and
should not stop Plavix(R) on their own.
Discontinuation of Plavix(R) in patients with
recently-placed stents can cause clot formation
within the stent, resulting in serious harm or
death. According to the 2006 ACC/AHA/SCAI
Guideline Update for Percutaneous Coronary
Intervention (PCI), Class I recommendations
indicate the use of aspirin and clopidigrel in
patients undergoing angioplasty with stent
implantation (contraindications include aspirin
resistance, allergy or risk of bleeding).
8
Safety Concerns Over DES
9
Proposed Long-Term Solution
Reference Prof Peter Fitzgerald (Stanford
University) at TCT 2005
10
Stent Evolution
Drug Eluting Stent No Polymer lt 2 Restenosis,
No late stent thrombosis No Plavix
Drug Eluting Stent Biodegradable Polymer lt5
Restenosis ,? Thrombosis 1 Year Plavix regimen
Drug Eluting Stent Durable Polymer lt5
Restenosis Late thrombosis Plavix Aspirin for
life
Bare Metal Stent 30 Restenosis
11
Matrix Structure Advancement

• Stent with thermal fused spheres for matrix
  formation
• Selective configuration for Endothelial cell
  growth
• Drug impregnated in multilayer surface to enhance
  release mechanism No POLYMER

SVI Bare Stent
12
Animal testing evidence
Naked Surface with metallic non-corrosive
material
13
Innovative Benefits
14
Growing Market
US6B and Growing!

• Growth of DES market will come from two areas
• Increasing rate of heart disease
• More doctors are choosing DES over bare-metal
  stents

Sources Analyst Reports, Company Data,
Management Estimates
15
Market Growth Potential
16
Competitive Landscape in China
All with Polymers
17
(No Transcript)
18
(No Transcript)
19
Exit Strategy

• IPO in Asia Market in 2011 / 2012
• Successful cases
• Biosensors went IPO in Singapore - Valuation
  gt600 Million
• Potential Acquisition from Strategic partner
• Successful cases
• .Conor MedSystem acquired by JJ for 1.4
  Billion ( Robert Ndondo Lays patent cited
  several times)
• . JWMS acquired by Biosensors for 140Million
  after 3 years of existence

20
Emerging from the Sea of DES without Polymer
Thank You